About Cardiff Oncology
Cardiff Oncology (NASDAQ:CRDF) is a biotechnology firm focused on developing new treatment options for cancer patients. Concentrating on oncology, the company leverages scientific innovations to create targeted solutions aiming to address the unmet needs within the cancer treatment landscape. Cardiff Oncology is particularly known for its commitment to advancing its lead drug candidate, onvansertib, through various phases of clinical trials in combination with standard-of-care therapies. The objective is to improve patient outcomes in cancers with significant unmet need, including colorectal, pancreatic, and prostate cancers. Its projects are designed to disrupt cancer cell growth and resistance, demonstrating the company's dedication to pushing the boundaries of cancer treatment. Through strategic partnerships and ongoing research, Cardiff Oncology seeks to unlock new possibilities in oncology, providing hope and new options for patients and their families.
Snapshot
Operations
Products and/or services of Cardiff Oncology
- Onvansertib, a PLK1 inhibitor being developed for the treatment of KRAS-mutated colorectal cancer, showing promise in combination with standard-of-care treatments.
- Clinical trials for Onvansertib targeting Acute Myeloid Leukemia (AML), exploring its effectiveness in halting cancer cell progression.
- Studies of Onvansertib in Castrate-Resistant Prostate Cancer (CRPC), investigating its ability to enhance the effectiveness of androgen deprivation therapy.
- Research into Onvansertib's applications in Non-Small Cell Lung Cancer (NSCLC), focusing on patients with specific genetic mutations.
- Development of Onvansertib for treatment of Triple-Negative Breast Cancer (TNBC), aiming to offer a new therapeutic option for this difficult-to-treat cancer type.
- Investigation into the combination of Onvansertib with targeted therapies across various cancer types, seeking synergistic effects that improve treatment outcomes.
Cardiff Oncology executive team
- Dr. Mani Mohindru Ph.D.Interim CEO & Director
- Ms. Brigitte LindsayChief Accounting Officer
- Dr. Tod Smeal Ph.D.Chief Scientific Officer
- Ms. Elizabeth AndersonVP of Finance & Administration
- Mr. Charles Monahan R.Ph.Senior Vice President of Regulatory Affairs
- Dr. Roger Sidhu M.D.Chief Medical Officer